Pharmacokinetics of Epinephrine During Cardiac Arrest

Pharmacokinetic Study of Epinephrine During Cardiac Arrest Determining T1/2 and Time to Peak Concentration

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03036202

Enrollment

Registered

2017-01-30

Start date

2017-06-26

Completion date

2018-10-12

Last updated

2019-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Arrest

Keywords

epinephrine

Brief summary

To determine the pharmacokinetics of epinephrine during cardiac arrest.

Detailed description

The aim of out study is to determine the pharmacokinetics in humans during cardiac arrest, following a single dose of epinephrine. Venous samples will be withdrawn every minute the first five minutes following a single dose. The aim of the study is to determine T1/2 in a clinical setting and to determine time to peak concentration.

Interventions

DRUGEpinephrine

This is truly an observational study to determine T1/2 for epinephrine and time to peak concentration following a single dose of epinephrine in a cardiac arrest setting

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Age 18-85 yrs * Witnessed non-traumatic cardiac arrest. * Probable cardiac origin * Treated by Bergen Emergency Medical Services

Exclusion criteria

* Terminal illness * Residents of nursery homes * Obvious dead * Hypothermic patients * Epinephrine administered before arrival of study physician

Design outcomes

Primary

Measure	Time frame	Description
Concentration of epinephrine (ng/mL) as a function of time the first five minutes following administration	Blood samples will be drawn within minutes, and the survivors transported to hospital. The data according to Utstein-style, will also be collected. Blood samples will be analysed within weeks.Total timeframe for the study is estimated to one year.	Blood concentration of epinephrine will be determined the first five minutes following administration. For every minute starting With administration of epinephrine, blood samples will be drawn to determine the concentration (ng/mL). In total, six samples will be drawn. The administered dose (1 mg) will also be related to the patients weight, either estimated, or for those survivors admitted to hospital, measured in the Intensive Care Unit. Further, data according to the Utstein-template will be recorded.However, the primary outcome is to determine the plasma concentrations in every patients the first five minutes.

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026